Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.

Journal of Clinical Lipidology
Harold BaysJames A Underberg

Abstract

Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus (T2DM) by reducing renal glucose reabsorption. The aim was to evaluate the lipid effects of dapagliflozin 10 mg or placebo in patients with T2DM with/without baseline elevated triglyceride and reduced high-density lipoprotein (HDL) cholesterol levels. This was a post hoc analysis of 10 phase 3, placebo-controlled studies of dapagliflozin 10 mg (N = 2237) or placebo (N = 2164) administered for 24 weeks in patients with T2DM. Patients with elevated triglyceride (≥150 mg/dL [1.69 mmol/L]) and reduced HDL cholesterol levels (<40 mg/dL [1.04 mmol/L] in men; <50 mg/dL [1.29 mmol/L] in women) were included (group A). The reference group (group B) included patients who did not meet the defined lipid criteria. The effects of dapagliflozin on fasting lipid profiles were generally similar in the 2 lipid groups (ie, groups A and B) and, compared with placebo, were associated with minor increases in non-HDL cholesterol, low-density lipoprotein, and HDL cholesterol levels. The effects on triglyceride levels were inconsistent. The incidence of adverse events (AEs)/serious AEs, and AEs of genital infec...Continue Reading

Citations

Apr 28, 2018·Current Opinion in Cardiology·Kalliopi PafiliNikolaos Papanas
Jan 16, 2019·Expert Review of Clinical Pharmacology·Angelo Maria PattiAli A Rizvi
Apr 22, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nienke M A IdzerdaHiddo J L Heerspink
Apr 1, 2020·Journal of Clinical Medicine·Angelo Maria PattiFerdinando Mannello
Jul 9, 2020·Alimentary Pharmacology & Therapeutics·Margery A ConnellyArun J Sanyal
Sep 16, 2019·Current Cardiology Reports·Cezary Wojcik, Bruce A Warden
Oct 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Sempastian Filippas-NtekouanMoses Elisaf

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.